Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Non-Current Deffered Revenue: 2020-2023

  • Molecular Partners Ag's Non-Current Deffered Revenue fell 71.81% to $1.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.6 million, marking a year-over-year decrease of 71.81%. This contributed to the annual value of $3.8 million for FY2022, which is 49.73% down from last year.
  • Per Molecular Partners Ag's latest filing, its Non-Current Deffered Revenue stood at $1.6 million for Q2 2023, which was down 58.14% from $3.8 million recorded in Q4 2022.
  • In the past 5 years, Molecular Partners Ag's Non-Current Deffered Revenue registered a high of $7.5 million during Q4 2021, and its lowest value of $1.6 million during Q2 2023.
  • Over the past 3 years, Molecular Partners Ag's median Non-Current Deffered Revenue value was $4.7 million (recorded in 2022), while the average stood at $4.6 million.
  • Per our database at Business Quant, Molecular Partners Ag's Non-Current Deffered Revenue soared by 131.01% in 2021 and then plummeted by 71.81% in 2023.
  • Quarterly analysis of 4 years shows Molecular Partners Ag's Non-Current Deffered Revenue stood at $3.3 million in 2020, then skyrocketed by 131.01% to $7.5 million in 2021, then tumbled by 49.73% to $3.8 million in 2022, then slumped by 71.81% to $1.6 million in 2023.
  • Its Non-Current Deffered Revenue stands at $1.6 million for Q2 2023, versus $3.8 million for Q4 2022 and $5.6 million for Q2 2022.